Impact of radiotherapy with and without concurrent cisplatin on lymphocyte subpopulations in cervical cancer patients

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4673-4678

  Bachtiary, Barbara ^a   Herbacek, Irene ^b   Zideck, Thomas ^b   Knocke, Thomas Hendrik ^a   Dimopoulos, Johannes ^a   Poetter, Richard ^a   Micksche, Michael ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cervical cancer; Lymphocyte subpopulations; Radio chemotherapy; Radiotherapy

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CD4-CD8 RATIO; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOCYTE SUBSETS; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; T-LYMPHOCYTES; UTERINE CERVICAL NEOPLASMS;

EID: 28444493280     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Peters WA III, Liu PY, Barrett RJ II, Stock RJ, Monk BJ, Berek JS et al: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18(8): 1606-1613, 2000.
2. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL III et al: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340(15): 1154-1161, 1999.
3. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE et al: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340(15): 1137-1143, 1999.
4. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr et al: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 77(5): 1339-1348, 1999.
5. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA et al: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340(15): 1144-1153, 1999.
6. Thomas GM: Concurrent chemotherapy and radiation for locally advanced cervical cancer: the new standard of care. Semin Radiat Oncol 10(1): 44-50, 2000.
7. Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M and Williams CJ: A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 68(3): 217-226, 2003.
8. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, Pecorelli S et al: Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 48(4): 997-1006, 2000.
9. Potter R, Van Limbergen E, Gerstner N and Wambersie A: Survey of the use of the ICRU 38 in recording and reporting cervical cancer brachytherapy. Radiother Oncol 58(1): 11-18, 2001.
10. Yamagata S and Green GH: Radiation-induced immune changes in patients with cancer of the cervix. Br J Obstet Gynaecol 83(5): 400-408, 1976.
11. Louagie H, Van Eijkeren M, Philippe J, Thierens H and de Ridder L: Changes in peripheral blood lymphocyte subsets in patients undergoing radiotherapy. Int J Radiat Biol 75(6): 767-771, 1999.
12. Gray WC, Chretien PB, Suter CM, Revie DR, Tomazic VT, Blanchard CL et al: Effects of radiation therapy on T-lymphocyte subpopulations in patients with head and neck cancer. Otolaryngol Head Neck Surg 93(5): 650-660, 1985.
13. Mackall CL: T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Oncologist 4(5): 370-378, 1999.
14. Masur H, Ognibene FP, Yarchoan R, Shelhamer JH, Baird BF, Travis W et al: CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 111(3): 223-231, 1989.
15. Hopfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B et al: Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 356(9246): 1985-1986, 2000.
16. Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J et al: Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 11(5): 483-488, 2002.
17. Brittenden J, Heys SD, Ross J and Eremin O: Natural killer cells and cancer. Cancer 77: 1226-1234, 1996.
18. Balaram P, Pillai MR, Padmanabhan TK, Abraham T, Hareendran NK and Nair MK: Immune function in malignant cervical neoplasia: a multiparameter analysis. Gynecol Oncol 31(3): 409-423, 1988.
19. Radhakrishna Pillai M, Balaram P, Chidambaram S, Padmanabhan TK and Nair MK: Development of an immunological staging system to prognosticate disease course in malignant cervical neoplasia. Gynecol Oncol 37(2): 200-205, 1990.
20. Tate DR and Anderson RJ: Recrudescence of cervical dysplasia among women who are infected with the human immunodeficiency virus: a case-control analysis. Am J Obstet Gynecol 186(5): 880-882, 2002.
21. Ahmed RS, Kim RY, Duan J, Meleth S, De Los Santos JF and Fiveash JB: IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys 60(2): 505-512, 2004.